Comparison of prednisolone, etoricoxib, and indomethacin in treatment of acute gouty arthritis: An open-label, randomized, controlled trial

Medical Science Monitor

Volumn 22, Issue , 2016, Pages 810-817

  Xu, Lingling ^a   Liu, Shiqun ^a   Guan, Meiping ^a   Xue, Yaoming ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Arthritis; Gouty; Indomethacin; Inflammation; Prednisolone

Indexed keywords

ETORICOXIB; INDOMETACIN; PREDNISOLONE; PYRIDINE DERIVATIVE; SULFONE;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADULT; ARTICLE; CLINICAL ASSESSMENT; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHEMA; FATIGUE; FEMALE; GOUT; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SWELLING; TREATMENT RESPONSE; XEROSTOMIA; ARTHRITIS, GOUTY; COMPARATIVE STUDY; CONTROLLED STUDY; PAIN MEASUREMENT; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; ARTHRITIS, GOUTY; FEMALE; HUMANS; INDOMETHACIN; MALE; PAIN MEASUREMENT; PREDNISOLONE; PYRIDINES; RECURRENCE; SULFONES; TREATMENT OUTCOME;

EID: 84961244976     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.895749     Document Type: Article

References (26)

1. Kim KY, Ralph Schumacher H, Hunsche E et al: A literature review of the epidemiology and treatment of acute gout. Clin Ther, 2003; 25(6): 1593–617.
2. Smith E, Hoy D, Cross M et al: The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis, 2014; 73(8): 1470–76.
3. Jordan KM, Cameron JS, Snaith M et al: British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford), 2007; 46(8): 1372–74.
4. Mandell BF: Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med, 2008; 75(Suppl.5): S5–8.
5. Eggebeen AT: Gout: an update. Am Fam Physician, 2007; 76(6): 801–8.
6. Richette P, Bardin T: Gout. Lancet, 2010; 375(9711): 318–28.
7. Terkeltaub RA: Clinical practice. Gout. N Engl J Med, 2003; 349(17): 1647–55.
8. Landis RC, Haskard DO: Pathogenesis of crystal-induced inflammation. Curr Rheumatol Rep, 2001; 3(1): 36–41.
9. Wechalekar MD, Vinik O, Moi JH et al: The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors. J Rheumatol Suppl, 2014; 92: 15–25.
10. Kim A, Jung BH, Cadet P: A novel pathway by which the environmental toxin 4-Nonylphenol may promote an inflammatory response in inflammatory bowel disease. Med Sci Monit Basic Res, 2014; 20: 47–54.
11. Khanna D, Khanna PP, Fitzgerald JD et al: 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken), 2012; 64(10): 1447–61.
12. Terkeltaub RA, Schumacher HR, Carter JD et al: Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther, 2013; 15(1): R25.
13. Man CY, Cheung IT, Cameron PA, Rainer TH: Comparison of oral prednisolone/ paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med, 2007; 49(5): 670–77.
14. Schumacher HR Jr, Boice JA, Daikh DI et al: Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ, 2002; 324(7352): 1488–92.
15. Li T, Chen SL, Dai Q et al: Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial. Chin Med J (Engl), 2013; 126(10): 1867–71.
16. Rubin BR, Burton R, Navarra S et al: Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum, 2004; 50(2): 598–606.
17. van Durme CM, Wechalekar MD, Buchbinder R et al: Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev, 2014; 9: CD010120.
18. Simmons DL, Botting RM, Hla T: Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev, 2004; 56(3): 387–437.
19. Scheiman JM: Outcomes studies of the gastrointestinal safety of cyclooxygenase- 2 inhibitors. Cleve Clin J Med, 2002; 69(Suppl.1): SI40–46.
20. Janssens HJ, Janssen M, van de Lisdonk EH et al: Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet, 2008; 371(9627): 1854–60.
21. Wallace SL, Robinson H, Masi AT et al: Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum, 1977; 20(3): 895–900.
22. Underwood M: Diagnosis and management of gout. BMJ, 2006; 332(7553): 1315–19.
23. Lawrence RC, Felson DT, Helmick CG et al: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum, 2008; 58(1): 26–35.
24. Petersel D, Schlesinger N: Treatment of acute gout in hospitalized patients. J Rheumatol, 2007; 34(7): 1566–68.
25. Krishnan E, Baker JF, Furst DE, Schumacher HR: Gout and the risk of acute myocardial infarction. Arthritis Rheum, 2006; 54(8): 2688–96.
26. Garcia Rodriguez LA, Hernandez-Diaz S: The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res, 2001; 3(2): 98–101